Get the content you want anytime you want.

Populations at Risk for Flu-associated Complications and Recommended Treatments


Rebekah Stewart Schicker, MSN, MPH, APRN, Epidemic Intelligence Service (EIS) Officer at the Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Influenza Division, discusses which outpatient populations are at highest risk of influenza-associated complications and recommended treatments.
Interview Transcript (slightly modified for readability)
"The outpatient population that’s considered at high risk for influenza-associated complications [include] children younger than 2 years, adults 65 and older, pregnant women, and people with certain underlying health conditions, such as asthma, diabetes, heart disease, or chronic obstructive pulmonary disease, or immunosuppression, among others.
The treatment for influenza among patients at high risk, or among any person who’s hospitalized, or has progressive influenza illness is a neurominidase inhibitor. Really, neurominidase inhibitors are the only approved treatment for influenza, and they include medications such as oseltamivir (Tamiflu), or zanamivir (Relenza) or peramivir [(Rapivab)]. Oseltamivir (Tamiflu), is the most commonly used one in the outpatient setting and it’s recommended as early as possible after symptoms start. The benefits are seen most when it’s started within two days of symptom onset."
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.

Want more information on this topic and the opportunity to ask questions of an expert? Register for a live, ACPE accredited webinar February 28th 8-9 PM EST at this link:
Big advances in treatment can